OXiGENE Inc. (OXGN) announced Tuesday that it is exploring regulatory approval for ZYBRESTAT in anaplastic thyroid cancer, in the European Union.
OXiGENE has been rising sharply since the open of trade Tuesday and is now up 1.15 at $4.53 on strong volume. The stock has surged to a 2-month high.
For comments and feedback: editorial@rttnews.com